5 Off label uses for psoriasis, hidradenitis suppurativa, acanthosis nigricans (AN), and Hailey-Hailey disease (HDD) have been reported
It helps you eat less without feeling deprived, leading to consistent, sustainable weight loss over time
You can find out more about our additional support through our coaching service
WEGOVY- semaglutide tablet, DailyMed (2026) Lillys oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity, Lilly (2025) Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes, a randomized clinical trial, JAMA Network Open (2023) Pfizer provides update on oral GLP-1 receptor agonist danuglipron, Pfizer (2025) Oral semaglutide, Clinical Diabetes (2020) Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet (2023) A review of current guidelines for the treatment of obesity, American Journal of Managed Care (2022) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Individual Variation: Metabolism, Genetics, and Provider Oversight While the 7-day half-life applies broadly, individual factors including body composition, liver function, kidney function, and genetic variants in drug-metabolizing enzymes may influence how quickly or slowly your body processes semaglutide
